UTHR

Liquidia’s share price has fluctuated sharply, raising questions about whether the current valuation reflects its earnings potential. The company’s recent volatility makes it hard to determine if the price is justified.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 33.8% over the past six months, topping the S&P 500 by 24.7 percentage points.

State Street’s SPDR S&P MidCap 400 ETF added $66.3 million worth of Okta stock on October 21, expanding its holdings to 398 positions. No shares were sold during the transaction.

United Therapeutics sees limited near‑term upside for its Tyvaso drug after the Liquidia settlement, according to RBC.

RBC Capital keeps an Outperform rating on United Therapeutics but cuts its price target from $708 to $697.

SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C., October 22, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors has authorized a new share repurchase program for up to $2 billion of the company’s common stock, available through October 21, 2027.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., October 21, 2026--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a press release that will be issued on Wednesday, November 4, 2026, at approximately 6:30 a.m. Eastern Time.

United Therapeutics Corporation (NASDAQ:UTHR) develops treatments for pulmonary arterial hypertension, a rare and dangerous high blood pressure in the lungs, with its Tyvaso franchise at the core. At about $23.5 billion in market value, it is one of the steadiest earners in biotech, and that is the whole point for index purposes. Most drug developers […]